Sponsor Pipeline

LIB Therapeutics LLC Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
2
Active Trials
0
Recruiting
2
Phase 3
1
Disease Areas
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-29 NCT07102511
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With…		 Enrolling by invitation only
2026-07-29 NCT07102511
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With…		 Trial sites expanded: 3 -> 7 locations
2026-07-29 NCT07102511
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With…		 date change Primary completion pushed: 2026-12-31 -> 2028-07-31
2026-07-29 NCT07102511
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With…		 date change Completion pushed: 2027-06-30 -> 2028-11-30
Active Trials by Phase
Phase 3
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT04798430 Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients… Cardiovascular Disease With Mention of Arteriosclerosis Enrolling by Invitation
NCT07102511 Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With… Familial Hypercholesterolemia - Heterozygous Enrolling by Invitation
Disease Areas
Heart Disease (1)
Get alerts when LIB Therapeutics LLC's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free